Search clinical trials for: AZD7442 IV

Total 3255 results

AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
MediMergent, LLC

Terminated

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

SARS-CoV-2 Infection

United States
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
University of Rome Tor Vergata

Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

COVID-19 Pandemic | Transplant-Related Disorder

Italy
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Completed

A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions

Healthy

Sweden
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers (SAD)

Healthy

Sweden
National Cancer Institute (NCI)

Completed

AZD7451 for Recurrent Gliomas

Glioblastoma Multiforme

United States
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Completed

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

Antiplatelet Effect
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses

Healthy

Japan
AstraZeneca

Completed

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

SARS-CoV-2

United States, Belgium, United Kingdom, Brazil, Germany
AstraZeneca

Not yet recruiting

eVusheld Assessment reaL wORld Effectiveness in DoD Health System (VALOR DoD)

COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
AstraZeneca

Completed

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Adult ADHD

United States
AstraZeneca

Completed

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (ROBIN)

Mild to Moderate Alzheimer's Disease

Czech Republic, Hungary, Slovakia
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446

Healthy

Sweden
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
AstraZeneca
Parexel

Completed

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject

Healthy

Japan
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
AstraZeneca

Completed

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Asthma

New Zealand, United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
Taipei City Hospital

Not yet recruiting

TCHCCT-Zhong-Xing-Emergency-Department Ultrasound With IV Contrast in Acute Flank Pain

Acute Flank Pain

Taiwan
AstraZeneca
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Healthy Subjects (Indication: Asthma)

United Kingdom
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
AstraZeneca

Completed

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Asthma

United Kingdom
AstraZeneca

Completed

Positron Emission Tomography (PET) Study

Healthy

Sweden
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
Asir John Samuel
Maharishi Markendeswar University (Deemed to be University)

Recruiting

Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes

Acute Coronary Syndrome

India
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Bioavailability

United States
Eli Lilly and Company

Completed

A Study of LY3475766 in Healthy Participants

Dyslipidemias

United States

3

Subscribe